Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 10 (October)

1. Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study.
   Br J Cancer, 99(7): 1040-5. [Abstract] [Full-text]
2. Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion.
   Br J Cancer, 99(7): 1114-20. [Abstract] [Full-text]
3. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells.
   J Cell Physiol, 217(3): 569-76. [Abstract] [Full-text]
4. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo.
   Carcinogenesis, 29(10): 2001-10. [Abstract] [Full-text]
5. Novel amiodarone-doxorubicin cocktail liposomes enhance doxorubicin retention and cytotoxicity in DU145 human prostate carcinoma cells.
   J Med Chem, 51(19): 6067-74. [Abstract] [Full-text]
6. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.
   J Biol Chem, 283(41): 27707-16. [Abstract] [Full-text]
7. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
   Int J Cancer, 123(11): 2636-43. [Abstract] [Full-text]
8. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
   Int J Cancer, 123(11): 2574-9. [Abstract] [Full-text]
9. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk.
   Int J Cancer, 123(11): 2644-50. [Abstract] [Full-text]
10. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38.
    Int J Cancer, 123(11): 2532-42. [Abstract] [Full-text]
11. Validation of quality indicators for radical prostatectomy.
    Int J Cancer, 123(11): 2651-7. [Abstract] [Full-text]
12. Definitive radiotherapy for prostate cancer.
    Am J Clin Oncol, 31(5): 496-503. [Abstract] [Full-text]
13. Metastatic prostatic carcinoma presenting as fulminant hepatic failure.
    South Med J, 101(10): 1049-50. [Abstract] [Full-text]
14. Perceived family history risk and symptomatic diagnosis of prostate cancer: the North Carolina Prostate Cancer Outcomes study.
    Cancer, 113(8): 2180-7. [Abstract] [Full-text]
15. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.
    Cancer, 113(8): 2068-72. [Abstract] [Full-text]
16. Predictors of patient preferences and treatment choices for localized prostate cancer.
    Cancer, 113(8): 2058-67. [Abstract] [Full-text]
17. Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy.
    Pathol Int, 58(11): 687-94. [Abstract] [Full-text]
18. Antidiabetic medication and prostate cancer risk: a population-based case-control study.
    Am J Epidemiol, 168(8): 925-31. [Abstract] [Full-text]
19. An N-terminal 78 amino acid truncation of REIC/Dkk-3 effectively induces apoptosis.
    Biochem Biophys Res Commun, 375(4): 614-8. [Abstract] [Full-text]
20. TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells.
    BMC Cancer, 8: 282. [Abstract] [Full-text]
21. Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care.
    Arch Intern Med, 168(18): 2033-40. [Abstract] [Full-text]
22. Is PTEN loss associated with clinical outcome measures in human prostate cancer?
    Br J Cancer, 99(8): 1296-301. [Abstract] [Full-text]
23. Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer.
    Mol Cancer Res, 6(10): 1639-48. [Abstract] [Full-text]
24. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
    Mol Cancer Res, 6(10): 1594-606. [Abstract] [Full-text]
25. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.
    Cancer Res, 68(20): 8607-15. [Abstract] [Full-text]
26. A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling.
    Cancer Res, 68(20): 8564-72. [Abstract] [Full-text]
27. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice.
    Cancer Res, 68(20): 8555-63. [Abstract] [Full-text]
28. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.
    Cancer Res, 68(20): 8516-24. [Abstract] [Full-text]
29. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    J Clin Oncol, 26(30): 4928-33. [Abstract] [Full-text]
30. The significance of monoamine oxidase-A expression in high grade prostate cancer.
    J Urol, 180(5): 2206-11. [Abstract] [Full-text]
31. Mass screening for prostate cancer in Korea: a population based study.
    J Urol, 180(5): 1949-52; discussion 1952-3. [Abstract] [Full-text]
32. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    J Urol, 180(5): 1975-8; discussion 1978-9. [Abstract] [Full-text]
33. Physician clinical experience and inappropriate prostate specific antigen screening: evidence from an Asian country.
    J Urol, 180(5): 1954-8; discussion 1958. [Abstract] [Full-text]
34. Prostate specific antigen assay standardization bias could affect clinical decision making.
    J Urol, 180(5): 1959-62; discussion 1962-3. [Abstract] [Full-text]
35. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    J Urol, 180(5): 1980-4; discussion 1985. [Abstract] [Full-text]
36. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    J Urol, 180(5): 2005-9; discussion 2009-10. [Abstract] [Full-text]
37. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
    J Urol, 180(5): 1964-7; discussion 1967-8. [Abstract] [Full-text]
38. Patterns of care for radical prostatectomy in the United States from 2003 to 2005.
    J Urol, 180(5): 1969-74. [Abstract] [Full-text]
39. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    J Urol, 180(5): 2011-7; discussion 2017-8. [Abstract] [Full-text]
40. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    J Urol, 180(5): 1986-92. [Abstract] [Full-text]
41. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    J Urol, 180(5): 1938-41; discussion 1941. [Abstract] [Full-text]
42. Immunocytological and preliminary immunohistochemical studies of prothymosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody.
    J Histochem Cytochem, 56(11): 1023-31. [Abstract] [Full-text]
43. The autocrine human secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53.
    Cancer Lett, 271(1): 64-80. [Abstract] [Full-text]
44. Molecular alterations in prostate cancer.
    Cancer Lett, 271(1): 13-24. [Abstract] [Full-text]
45. Verification of dose delivery for a prostate sIMRT treatment using a SLIC-EPID.
    Appl Radiat Isot, 66(12): 1930-8. [Abstract] [Full-text]
46. Measurement and comparison of skin dose for prostate and head-and-neck patients treated on various IMRT delivery systems.
    Appl Radiat Isot, 66(12): 1844-9. [Abstract] [Full-text]
47. The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression.
    BMC Cancer, 8: 273. [Abstract] [Full-text]
48. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.
    Adv Anat Pathol, 15(6): 319-31. [Abstract] [Full-text]
49. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR.
    BMC Cancer, 8: 284. [Abstract] [Full-text]
50. The effect of hospital and surgeon volume on racial differences in recurrence-free survival after radical prostatectomy.
    Med Care, 46(11): 1170-6. [Abstract] [Full-text]
51. Do prostatic transition zone tumors have a distinct morphology?
    Am J Surg Pathol, 32(11): 1709-14. [Abstract] [Full-text]
52. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review.
    Int J Radiat Oncol Biol Phys, 72(4): 972-9. [Abstract] [Full-text]
53. Calcifications are potential surrogates for prostate localization in image-guided radiotherapy.
    Int J Radiat Oncol Biol Phys, 72(4): 963-6. [Abstract] [Full-text]
54. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 72(4): 980-8. [Abstract] [Full-text]
55. Quality of life in men treated with carbon ion therapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 72(4): 1010-5. [Abstract] [Full-text]
56. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy.
    Int J Radiat Oncol Biol Phys, 72(4): 996-1001. [Abstract] [Full-text]
57. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer.
    Int J Radiat Oncol Biol Phys, 72(4): 1002-9. [Abstract] [Full-text]
58. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.
    Int J Radiat Oncol Biol Phys, 72(4): 989-95. [Abstract] [Full-text]
59. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
    Oncology, 75(3): 230-6. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.